👉 Share your findings with regional and international experts in #cancer #drugdevelopment.
⏰ You still have 3 weeks to submit your abstract to #ESMOTATAsia25, a new platform to improve cancer care in the region
Submit now:
🔗 buff.ly/IdnoYdO
⏰ You still have 3 weeks to submit your abstract to #ESMOTATAsia25, a new platform to improve cancer care in the region
Submit now:
🔗 buff.ly/IdnoYdO
April 4, 2025 at 2:03 PM
Everybody can reply
1 reposts
4 likes
#ESMOTATAsia25: Exploratory #omics and #MachineLearning revealed an 11-gene signature associated with response after #chemoradiotherapy for #CervicalCancer. MMP2 was identified as a key target.
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
July 19, 2025 at 8:15 AM
Everybody can reply
1 reposts
3 likes
One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
July 11, 2025 at 7:36 PM
Everybody can reply
2 reposts
7 likes
#ESMOTATAsia25: In an Opinion piece in the #ESMODailyReporter, Lillian Siu discusses the growth of early #oncology #ClinicalTrials in #AsiaPacific but highlights the need for improved trial access in low- and middle-income countries.
🔗 dailyreporter.esmo.org/esmo-targete...
🔗 dailyreporter.esmo.org/esmo-targete...
July 19, 2025 at 6:55 AM
Everybody can reply
2 reposts
2 likes
🙌 Welcome to #ESMOTATAsia25!
The Congress kicks off today — get ready for cutting-edge insights in targeted therapies and early drug development.
👉 Join us to accelerate novel cancer therapeutics across the APAC region: #Oncology #CancerResearch
🔗 buff.ly/wZIsR9E
The Congress kicks off today — get ready for cutting-edge insights in targeted therapies and early drug development.
👉 Join us to accelerate novel cancer therapeutics across the APAC region: #Oncology #CancerResearch
🔗 buff.ly/wZIsR9E
July 18, 2025 at 3:01 AM
Everybody can reply
3 likes
⏰ Less than 1 week left to submit your abstract to #ESMOTATAsia25. Let's accelerate the development of #earlyphasetrials in the region together.
👉 Submit your research by 29 April by 18:00 Hong Kong Time
🔗 buff.ly/nlzr3GY
👉 Submit your research by 29 April by 18:00 Hong Kong Time
🔗 buff.ly/nlzr3GY
April 23, 2025 at 9:32 AM
Everybody can reply
1 reposts
4 likes
#AntiDrugConjugates in #LungCancer. In an Opinion piece in the #ESMODailyReporter, Tony Mok reviews data from recent #ClinicalTrials using HER2-, HER3- on TROP2-targeted #ADCs.
🔗 buff.ly/293gWvr
#ESMOTATAsia25
🔗 buff.ly/293gWvr
#ESMOTATAsia25
July 20, 2025 at 7:00 AM
Everybody can reply
1 reposts
2 likes
Check out the Developmental Therapeutics Collection, highlighting therapeutics currently in preclinical to early clinical development. #ESMOTATAsia25
July 18, 2025 at 4:21 PM
Everybody can reply
1 reposts
1 likes
Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!
May 7, 2025 at 12:25 PM
Everybody can reply
2 reposts
4 likes
📖 The ESMO Targeted Anticancer Therapies Asia Congress 2025 resources are now available on OncologyPro. 🔗 buff.ly/OSLsJ2x
📚 Explore cutting-edge discoveries and expert-led discussions from #ESMOTATAsia25 - where the science of early-phase oncology meets innovation.
📚 Explore cutting-edge discoveries and expert-led discussions from #ESMOTATAsia25 - where the science of early-phase oncology meets innovation.
July 21, 2025 at 2:30 PM
Everybody can reply
1 reposts
3 likes
15 Posts Not to Miss from ESMO TAT Asia 2025
@myesmo.bsky.social
@jiajennyliu.bsky.social @anmwongnz.bsky.social @rashidlui.bsky.social @omalirp.bsky.social @herbloongmd.bsky.social
oncodaily.com/societies/15...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOTATAsia25
@myesmo.bsky.social
@jiajennyliu.bsky.social @anmwongnz.bsky.social @rashidlui.bsky.social @omalirp.bsky.social @herbloongmd.bsky.social
oncodaily.com/societies/15...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOTATAsia25
15 Posts Not to Miss from ESMO TAT Asia 2025 - OncoDaily
The ESMO Targeted Anticancer Therapies (ESMO TAT Asia 2025) Congress took place in Hong Kong SAR, China, from July 18 to 20, bringing to
oncodaily.com
July 24, 2025 at 11:06 PM
Everybody can reply
1 reposts
10 likes
Assistant Editor of Molecular Cancer Therapeutics, Danielle Large, PhD, will be attending #ESMOTATAsia25. Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at the journal!
July 17, 2025 at 4:17 PM
Everybody can reply
1 likes
⏰Less than 2 weeks left to submit your abstract to #ESMOTATAsia25! A fantastic opportunity to showcase your transformative work within the region in a truly international platform.
👉Submit your research by 29 April by 18:00 Hong Kong Time
🔗 buff.ly/nOD4Kzs
👉Submit your research by 29 April by 18:00 Hong Kong Time
🔗 buff.ly/nOD4Kzs
April 16, 2025 at 6:15 AM
Everybody can reply
2 reposts
6 likes
📣Final call for early registration! The #ESMOTATAsia25 early registration fees are ending soon.
⏰Register by 14 May and be part of the future of cancer #drugdevelopment.
🔗 buff.ly/e1yAPUD
⏰Register by 14 May and be part of the future of cancer #drugdevelopment.
🔗 buff.ly/e1yAPUD
May 7, 2025 at 3:00 AM
Everybody can reply
1 reposts
3 likes
Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn’t Miss
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOTATASIA25
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOTATASIA25
Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss - OncoDaily
Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss / cancer, CAR-T therapy, CT041, ESMO TAT Asia 2025, gastric cancer, immunotherapy,
oncodaily.com
July 30, 2025 at 11:27 PM
Everybody can reply
3 reposts
9 likes
Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't be shy - come by and say hi!
#drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023
#drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023
July 15, 2025 at 9:46 AM
Everybody can reply
2 likes
Did you know - Molecular Cancer Therapeutics is the central hub for #FirstDisclosures in cancer. Catch up on the latest articles: buff.ly/xzopCbo #ESMOTATAsia25
July 19, 2025 at 4:24 PM
Everybody can reply
#ESMOTATAsia25: Presentations highlight the value of integrating #PatientReportedOutcomes (#PRO) into #EarlyPhaseTrials with guidance on standardisation.
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
July 18, 2025 at 7:58 AM
Everybody can reply
2 reposts
3 likes